425: Cyclacel Shareholders Approve Merger, Name Change to Bio Green Med

Cyclacel Pharmaceuticals shareholders approved all three proposals at a special meeting, including a share issuance for Fitters Parent, a potential issuance of over 20% of common stock, and a corporate name change to Bio Green Med Solution, Inc.

Summary

• Shareholders of Cyclacel Pharmaceuticals, Inc. held a special meeting on September 4, 2025, where three key proposals were submitted for a vote.
• Proposal 1, concerning the approval of the issuance of Cyclacel common stock to Fitters Parent, was approved with 1,095,988 votes (58.8%) FOR.
• Proposal 2, regarding the approval of the potential issuance of more than 20% of the issued and outstanding shares of common stock in connection with the transaction to comply with Nasdaq Listing Rule 5635(a), was approved with 1,095,986 votes (58.8%) FOR.
• Proposal 3, to approve an amendment to the certificate of incorporation changing the corporate name to Bio Green Med Solution, Inc., permitting actions by stockholders by written consent, ratifying prior actions by written consent, and opting out of DGCL Section 203 business combination provisions, was approved with 1,097,489 votes (58.9%) FOR.

Sentiment

Score: 7

Explanation: The successful approval of all three key proposals, including a significant share issuance and a corporate name change, indicates strong shareholder support for the company's strategic direction and future plans, which is generally positive for corporate stability and execution. However, the full implications of the transaction and rebranding are yet to be seen.

Positives

• Shareholder approval for all strategic proposals, including the Fitters Parent transaction and corporate name change, indicates strong support for the company's future direction.
• The high percentage of 'FOR' votes (approximately 58.8-58.9%) across all proposals suggests broad shareholder alignment with management's strategic initiatives.
• The approval of amendments to the certificate of incorporation, including permitting actions by stockholders by written consent, could enhance corporate agility and efficiency.
• Opting out of DGCL Section 203 business combination provisions may remove certain restrictions on future strategic transactions, potentially making the company more attractive for mergers or acquisitions.

Future Outlook

The approvals pave the way for the transaction with Fitters Parent and the corporate rebranding to Bio Green Med Solution, Inc., signaling a new strategic direction for the company. The changes to corporate governance also indicate a forward-looking approach to corporate structure and flexibility.

Management Comments

• Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer and Executive Director, formally signed the report on behalf of Cyclacel Pharmaceuticals, Inc., acknowledging the shareholder vote outcomes.

Industry Context

This filing indicates a significant corporate restructuring and potential strategic shift for Cyclacel Pharmaceuticals, moving towards a new identity as Bio Green Med Solution, Inc., likely reflecting a change in business focus or a major acquisition/merger. The approval of share issuance for Fitters Parent suggests a strategic partnership or acquisition that could alter the company's competitive landscape and market positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: The approval of share issuance to Fitters Parent and the potential issuance of more than 20% of common stock could lead to dilution for existing shareholders. The name change and governance amendments signal a new strategic direction that may impact future value.
• Management/Employees: The corporate name change and strategic transaction with Fitters Parent likely indicate a significant shift in company focus or operations, which could impact employee roles, responsibilities, and the overall corporate culture.
• Customers/Partners: A corporate rebranding to Bio Green Med Solution, Inc. could signal a change in product or service offerings, potentially affecting existing customer relationships and future partnerships.

Next Steps

• Proceed with the issuance of common stock to Fitters Parent as per the Exchange Agreement.
• Implement the corporate name change to Bio Green Med Solution, Inc. by amending the certificate of incorporation.
• Update corporate documents to reflect the new provisions regarding stockholder actions by written consent and the opt-out of DGCL Section 203.

Key Dates

Recommendation

While the shareholder approval of key strategic initiatives, including a significant share issuance and a corporate name change, indicates a clear path forward and management's ability to execute its vision, the full details of the 'transaction' with Fitters Parent and the implications of the 'potential issuance of more than 20% of common stock' are not fully elaborated in this filing. The name change to 'Bio Green Med Solution, Inc.' suggests a significant pivot, which could introduce new opportunities but also new uncertainties regarding the company's core business and future strategy. Investors should hold and await further details on the strategic rationale, financial terms of the Fitters Parent transaction, and the new business focus under Bio Green Med Solution, Inc. before making a definitive buy or sell decision. The potential for significant dilution also warrants caution.

Keywords

Cyclacel Pharmaceuticals, Bio Green Med Solution, Fitters Parent, Shareholder Meeting, Corporate Name Change, Stock Issuance, Nasdaq Listing Rule 5635(a), Corporate Governance, Merger, Acquisition